Serum NGAL can act as an early renal safety biomarker during long-term nucleos(t)ide analogue antiviral therapy in chronic hepatitis B
Journal article published in 2018 by
I. Carey 
,
R. Byrne,
K. Childs,
M. Horner,
M. Bruce,
B. Wang ,
G. Dusheiko,
K. Agarwal
,
R. Byrne,
K. Childs,
M. Horner,
M. Bruce,
B. Wang ,
G. Dusheiko,
K. Agarwal
This paper was not found in any repository, but could be made available legally by the author.
Full text: Unavailable
Published version:
archiving forbidden
Data provided by 